SCHEMBL17317812

SCHEMBL17317812

COC(=O)C12CCC(CC(=O)O)(CC1)CC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.40
NPSR1 Q6W5P4 1/20 0.34
HSD11B1 P28845 1/20 0.33
CYP4F2 P78329 1/20 0.33
CYP4A11 Q02928 1/20 0.33
CYP2C19 P33261 1/20 0.32
GRM1 Q13255 1/20 0.32
ADORA2A P29274 1/20 0.32
ADORA1 P30542 1/20 0.32
CYP1A2 P05177 2/20 0.31
LMNA P02545 2/20 0.31
ALDH1A1 P00352 2/20 0.31
TSHR P16473 2/20 0.31
OPRM1 P35372 1/20 0.31
USP2 O75604 1/20 0.31
BLM P54132 1/20 0.31
CACNA2D1 P54289 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
DGAT1 O75907 1/20 0.30
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17317454 0.89 CHRM1 (0.35) CHRM1NPSR1CYP4F2CYP4A11CYP2C19
SCHEMBL23599607 0.82 CHRM1 (0.36) CHRM1NPSR1HSD11B1CYP4F2CYP4A11
SCHEMBL23540159 0.82 GRM1 (0.40) CHRM1NPSR1CYP4F2CYP4A11GRM1
SCHEMBL1502377 0.81 CHRM1 (0.38) CHRM1NPSR1HSD11B1CYP4F2CYP4A11
SCHEMBL2445606 0.80 NPSR1 (0.46) CHRM1NPSR1HSD11B1CYP4F2CYP4A11
SCHEMBL14087273 0.79 CHRM1 (0.39) CHRM1NPSR1HSD11B1CYP4F2CYP4A11
SCHEMBL10164849 0.79 CHRM1 (0.39) CHRM1NPSR1HSD11B1CYP4F2CYP4A11
SCHEMBL23369954 0.78 CHRM1 (0.38) CHRM1NPSR1HSD11B1CYP4F2CYP4A11
SCHEMBL16700329 0.78 CHRM1 (0.38) CHRM1NPSR1HSD11B1CYP4F2CYP4A11
SCHEMBL4743712 0.78 CHRM1 (0.38) CHRM1NPSR1HSD11B1CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof LG CHEM, LTD. (KR) 2026-05-26 US disclosed
CN-114901653-B Novel amide derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2024-11-22 CN disclosed
EP-4074701-B1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF LG CHEMICAL LTD (KR) 2023-12-13 EP disclosed
US-20230101389-A1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF LG CHEM, LTD. (KR) 2023-03-30 US disclosed
EP-4074701-A1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF Lg Chem, Ltd. (KR) 2022-10-19 EP disclosed
CN-114901653-A Novel amide derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2022-08-12 CN disclosed
WO-2022138791-A1 EP2 ANTAGONIST 小野薬品工業株式会社 2022-06-30 WO disclosed
WO-2021133038-A1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF 주식회사 엘지화학 2021-07-01 WO disclosed
US-10144732-B2 ATX modulating agents BIOGEN MA INC. (US) 2018-12-04 US disclosed
US-20170197960-A1 ATX MODULATING AGENTS BIOGEN MA INC. 2017-07-13 US disclosed
US-20170197960-A1 ATX MODULATING AGENTS BIOGEN MA INC. 2017-07-13 US disclosed
US-20170197960-A1 ATX MODULATING AGENTS BIOGEN MA INC. 2017-07-13 US disclosed
EP-3152206-A1 ATX MODULATING AGENTS Biogen MA Inc. (US) 2017-04-12 EP disclosed
WO-2015188051-A1 ATX MODULATING AGENTS BIOGEN MA INC. (US) 2015-12-10 WO disclosed
WO-2015188051-A1 ATX MODULATING AGENTS BIOGEN MA INC. (US) 2015-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197960-A1 ATX MODULATING AGENTS ENPP2, ATXN10, ATXN2 CHRM1 549/4885NPSR1 303/4885HSD11B1 3408/4885
US-20230101389-A1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF DGAT2, DGAT1, MOGAT2 CHRM1 4728/4885NPSR1 4118/4885HSD11B1 781/4885
US-10144732-B2 ATX modulating agents ENPP2, ATXN10, ATXN2 CHRM1 549/4885NPSR1 300/4885HSD11B1 3410/4885
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof DGAT2, DGAT1, DLAT CHRM1 4255/4885NPSR1 2962/4885HSD11B1 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.